MedTrace Logo

Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer

NCT00283608 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2011-05-16

No results posted yet for this study

Summary

RATIONALE: Studying samples of blood in the laboratory from patients with cancer receiving anastrozole may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about how anastrozole works in the body.

PURPOSE: This research study is looking at the pharmacogenetics of anastrozole in postmenopausal women with estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+) stage I, stage II, or stage III breast cancer.

Conditions

Interventions

GENETIC

Single nucleotide polymorphism (SNP)

Evaluating SNP association with traits.

OTHER

high performance liquid chromatography

analysis of plasma concentrations of drugs

OTHER

measurements by DXA

determine bone mineral density (BMD)

OTHER

questionnaire administration

determine attitude changes

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • James N. Ingle, MD · Mayo Clinic

  • Edith A. Perez, MD · Mayo Clinic

  • Donald W. Northfelt, MD, FACP · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00283608 on ClinicalTrials.gov